Novel drugs in familial combined hyperlipidemia: Lessons from type 2 diabetes mellitus

Current Opinion in Lipidology

Volumn 21, Issue 6, 2010, Pages 530-538

  Brouwers, Martijn C G J ^a   De Graaf, Jacqueline ^b   Van Greevenbroek, Marleen M J ^a   Schaper, Nicolaas ^a   Stehouwer, Coen D A ^a   Stalenhoef, Anton F H ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

familial combined hyperlipidemia; insulin resistance; thiazolidinediones; treatment; type 2 diabetes mellitus

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; FIBRIC ACID DERIVATIVE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; LAROPIPRANT; METFORMIN; NICOTINIC ACID; PIOGLITAZONE; ROSIGLITAZONE; THYROMIMETIC AGENT; TRANSCRIPTION FACTOR 7 LIKE 2; UPSTREAM STIMULATORY FACTOR 1;

ADD ON THERAPY; ADIPOSE TISSUE; CARDIOVASCULAR RISK; DIAGNOSTIC PROCEDURE; DISEASE COURSE; FAMILIAL COMBINED HYPERLIPIDEMIA; FAMILIAL HYPERLIPEMIA; FLUSHING; GENETIC ASSOCIATION; HEREDITY; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID STORAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ADIPOSE TISSUE; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; FATTY LIVER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; METFORMIN; MODELS, BIOLOGICAL; OBESITY; RISK FACTORS; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 78650307216     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32833ea9ec     Document Type: Review

References (105)

1. Goldstein JL, Schrott HG, Hazzard WR, et al. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52:1544-1568.
2. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipi-demia in coronary artery disease risk. J Clin Endocrinol Metab 2004; 89:2601-2607.
3. Pajukanta P, Nuotio I, Terwilliger JD, et al. Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. Nat Genet 1998; 18:369-373.
4. Vionnet N, Hani EH, Dupont S,et al. Genomewide searchfor type 2diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of atype 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 2000; 67:1470-1480.
5. Pajukanta P, Lilja HE, Sinsheimer JS, et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 2004; 36:371-376.
6. Huertas-Vazquez A, Aguilar-Salinas C, Lusis AJ, et al. Familial combined hyperlipidemia in Mexicans: association with upstream transcription factor 1 and linkage on chromosome 16q24.1. Arterioscler Thromb Vasc Biol 2005; 25:1985-1991.
7. van der Vleuten GM, Isaacs A, Hijmans A, et al. The involvement of upstream stimulatory factor 1 in Dutch patients with familial combined hyperlipidemia. J Lipid Res 2007; 48:193-200.
8. Zeggini E, Damcott CM, Hanson RL, et al. Variation within the gene encoding the upstream stimulatory factor 1 does not influence susceptibility to type 2 diabetes in samples from populations with replicated evidence of linkage to chromosome 1q. Diabetes 2006; 55:2541-2548.
9. Meex SJ, van Vliet-Ostaptchouk JV, van der Kallen CJ, et al. Upstream transcription factor 1 (USF1) in risk of type 2 diabetes: association study in 2000 Dutch Caucasians. Mol Genet Metab 2008; 94:352-355.
10. Ng MC, Miyake K, So WY, et al. The linkage and association of the gene encoding upstream stimulatory factor 1 with type 2 diabetes and metabolic syndrome in the Chinese population. Diabetologia 2005; 48:2018-2024.
11. Meex SJ, Weissglas-Volkov D, van der Kallen CJ, et al. The ATF6-Met[67]Val substitution is associated with increased plasma cholesterol levels. Arter-ioscler Thromb Vasc Biol 2009; 29:1322-1327.
12. Meex SJ, van Greevenbroek MM, Ayoubi TA, et al. Activating transcription factor 6 polymorphisms and haplotypes are associated with impaired glucose homeostasis and type 2 diabetes in Dutch Caucasians. J Clin Endocrinol Metab 2007; 92:2720-2725.
13. Thameem F, Farook VS, Bogardus C, Prochazka M. Association of amino acid variants in the activating transcription factor 6 gene (ATF6) on 1q21- q23 with type 2 diabetes in Pima Indians. Diabetes 2006; 55:839-842.
14. Love-Gregory LD, Wasson J, Ma J, et al. A common polymorphism in the upstream promoter region of the hepatocyte nuclear factor-4 alpha gene on chromosome 20q is associated with type 2 diabetes and appears to contribute to the evidence for linkage in an Ashkenazi Jewish population. Diabetes 2004; 53:1134-1140.
15. Damcott CM, Hoppman N, Ott SH, et al. Polymorphisms in both promoters of hepatocyte nuclear factor 4-alpha are associated with type 2 diabetes in the Amish. Diabetes 2004; 53:3337-3341.
16. Weissglas-VolkovD, Huertas-VazquezA,Suviolahti E,et al. Common hepatic nuclear factor-4alpha variants are associated with high serum lipid levels and the metabolic syndrome. Diabetes. 2006; 55: 1970-1977.
17. Huertas-Vazquez A, Plaisier C, Weissglas-Volkov D, et al. TCF7L2 is associated with high serum triacylglycerol and differentially expressed in adipose tissue in families with familial combined hyperlipidaemia. Diabetologia 2008; 51:62-69.
18. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38:320-323.
19. Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91:295-299.
20. Wang P, van Greevenbroek MM, Bouwman FG, et al. The circulating PBEF/ NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Arch 2007; 454:971-976.
21. van der Vleuten GM, van Tits LJ, den Heijer M, et al. Decreased adiponectin levels in familial combined hyperlipidemia patients contribute to the athero-genic lipid profile. J Lipid Res 2005; 46:2398-2404.
22. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20:1595-1599.
23. van der Kallen CJ, Voors-Pette C, Bouwman FG, et al. Evidence of insulin resistant lipid metabolism in adipose tissue in familial combined hyperlipi-demia, but not type 2 diabetes mellitus. Atherosclerosis 2002; 164:337-346.
24. Aitman TJ, Godsland IF, Farren B, et al. Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. Arterios-cler Thromb Vasc Biol 1997; 17:748-754.
25. Pihlajamaki J, Karjalainen L, Karhapaa P, et al. Impaired free fatty acid suppression during hyperinsulinemia is a characteristic finding in familial combined hyperlipidemia, but insulin resistance is observed only in hyper-triglyceridemic patients. Arterioscler Thromb Vasc Biol 2000; 20:164-170.
26. Kotronen A, Juurinen L, Tiikkainen M, et al. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology 2008; 135:122-130.
27. Venkatesan S, Cullen P, Pacy P, et al. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1993; 13:1110-1118.
28. Chait A, Albers JJ, Brunzell JD. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia. Eur J Clin Invest 1980; 10:17-22.
29. Kotronen A, Juurinen L, Hakkarainen A, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 2008; 31:165-169.
30. Brouwers MC, Bilderbeek-Beckers MA, Georgieva AM, et al. Fatty liver is an integral feature of familial combined hyperlipidaemia: relationship with fat distribution and plasma lipids. Clin Sci (Lond) 2007; 112:123-130.
31. Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol 2003; 92:27-33.
32. de Jager J, Dekker JM, Kooy A, et al. Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study. Arterioscler Thromb Vasc Biol 2006; 26:1086-1093.
33. Georgieva AM, Cate HT, Keulen ET, et al. Prothrombotic markers in familial combined hyperlipidemia: evidence of endothelial cell activation and relation to metabolic syndrome. Atherosclerosis 2004; 175:345-351.
34. Keulen ET, Voors-Pette C, de Bruin TW. Familial dyslipidemic hypertension syndrome: familial combined hyperlipidemia, and the role of abdominal fat mass. Am J Hypertens 2001; 14:357-363.
35. Brouwers MC, Reesink KD, van Greevenbroek MM, et al. Increased arterial stiffness in familial combined hyperlipidemia. J Hypertens 2009; 27:1009-1016.
36. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008; 51:527-539.
37. ter Avest E, Holewijn S, Bredie SJ, et al. Pulse wave velocity in familial combined hyperlipidemia. Am J Hypertens. 2007; 20: 263-269.
38. Brouwers MC, Govers-Riemslag J, Schalkwijk CG, et al. Plasma PAI-1 levels are independently related to fatty liver and hypertriglyceridemia in familial combined hyperlipidemia, involvement of apolipoprotein E. Thromb Res 2008; 122:466-472.
39. Juhan-Vague I, Roul C, Alessi MC, et al. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients: relationship with plasma insulin. Thromb Haemost 1989; 61:370-373.
40. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306:457-461.
41. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:E214-E223.
42. Krssak M, Falk Petersen K, Dresner A, et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectro-scopy study. Diabetologia 1999; 42:113-116.
43. He J, Watkins S, Kelley DE. Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity. Diabetes 2001; 50:817-823.
44. Nielsen S, Guo Z, Johnson CM, et al. Splanchnic lipolysis in human obesity. J Clin Invest 2004; 113:1582-1588.
45. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115:1343-1351.
46. Brouwers MC, Cantor RM, Kono N, et al. Heritability and genetic loci of fatty liver in familial combined hyperlipidemia. J Lipid Res 2006; 47:2799-2807.
47. Vakkilainen J, Jauhiainen M, Ylitalo K, et al. LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J Lipid Res 2002; 43:598-603.
48. Guerin M, Le Goff W, Lassel TS, et al. Atherogenic role of elevated CE transfer from HDL toVLDL(1) and dense LDLin type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 2001; 21:282-288.
49. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260:1917-1921.
50. Pauciullo P, Gentile M, Marotta G, et al. Small dense low-density lipoprotein in familial combined hyperlipidemia: independent of metabolic syndrome and related to history of cardiovascular events. Atherosclerosis 2009; 203:320-324.
51. de Graaf J, van der Vleuten GM, ter Avest E, et al. High plasma level of remnant-like particles cholesterol in familial combined hyperlipidemia. J Clin Endocrinol Metab 2007; 92:1269-1275.
52. Bredie SJ, Kiemeney LA, de Haan AF, et al. Inherited susceptibility determines the distribution of dense low-density lipoprotein subfraction profiles in familial combined hyperlipidemia. Am J Hum Genet 1996; 58:812-822.
53. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183-1197.
54. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: WHO; 1999.
55. Bredie SJ, Tack CJ, Smits P, Stalenhoef AF. Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaf-fected relatives. Arterioscler Thromb Vasc Biol 1997; 17:1465-1471.
56. de Graaf J, Couture P, Sniderman A. A diagnostic algorithm for the athero-genic apolipoprotein B dyslipoproteinemias. Nat Clin Pract Endocrinol Metab 2008; 4:608-618.
57. Veerkamp MJ, de Graaf J, Hendriks JC, et al. Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study. Circulation 2004; 109:2980-2985.
58. Sniderman AD, Castro Cabezas M, Ribalta J, et al. A proposal to redefine familial combined hyperlipidaemia: third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the scientific sessions of the European Society for Clinical Investigation. Eur J Clin Invest 2002; 32:71-73.
59. Brunzell JD, Albers JJ, Chait A, et al. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983; 24:147-155.
60. Brouwers MC, van Greevenbroek MM, Vermeulen VM, et al. Five-year follow-up of waist circumference, insulin and ALT levels in familial combined hyperlipidaemia. Clin Sci (Lond) 2007; 113:375-381.
61. Veerkamp MJ, de Graaf J, Bredie SJ, et al. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. ArteriosclerThromb Vasc Biol 2002; 22:274-282.
62. Veerkamp MJ, de Graaf J, Stalenhoef AF. Role of insulin resistance in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2005; 25:1026-1031.
63. Westerbacka J, Corner A, Tiikkainen M, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 2004; 47:1360-1369.
64. Adiels M, Westerbacka J, Soro-Paavonen A, et al. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 2007; 50:2356-2365.
65. Westerbacka J, Lammi K, Hakkinen AM, et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005; 90:2804-2809.
66. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997; 17:3542-3556.
67. Brouwers MC, de Graaf J, van Greevenbroek MM, et al. Parabolic relationship between plasma triacylglycerols and LDL-cholesterol in familial combined hyperlipidaemia: the multiple-type hyperlipidaemia explained? Clin Sci (Lond) 2008; 114:393-401.
68. Brouwers MC, Dekker JM, van Greevenbroek MM, et al. Plasma triglycerides and LDL cholesterol are related in a parabolic fashion in the general population and patients with Type 2 diabetes mellitus: long-term follow-up results from the Hoorn study. Diabet Med 2008; 25:1121-1124.
69. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8:1288-1295.
70. Orho-Melander M, Melander O, Guiducci C, et al. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 2008; 57:3112-3121.
71. Weissglas-Volkov D, Aguilar-Salinas CA, Sinsheimer JS, et al. Investigation of variants identified in Caucasian genome-wide association studies for plasma high-density lipoprotein cholesterol and triglycerides levels in Mexican dyslipidemic study samples. Circ Cardiovasc Genet 2010; 3:31-38.
72. den Boer MA, Voshol PJ, Kuipers F, et al. Hepatic glucose production is more sensitive to insulin-mediated inhibition than hepatic VLDL-triglyceride production. Am J Physiol Endocrinol Metab 2006; 291:E1360-E1364.
73. Brouwers MC, van der Kallen CJ, Schaper NC, et al. Five-year incidence of type 2 diabetes mellitus in patients with familial combined hyperlipidaemia. Neth J Med 2010; 68:163-167.
74. Ter Avest E, Sniderman AD, Bredie SJ, et al. Effect of aging and obesity on the expression of dyslipidaemia in children from families with familial combined hyperlipidaemia. Clin Sci (Lond) 2007; 112:131-139.
75. Van Himbergen TM, Otokozawa S, Matthan NR, et al. Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway. Arterioscler Thromb Vasc Biol 2010; 30:113-120.
76. Wojciechowski AP, Farrall M, Cullen P, et al. Familial combined hyperlipidaemia linked to the apolipoprotein AI-CII-AIV gene cluster on chromosome 11q23-q24. Nature 1991; 349:161-164.
77. Coon H, Myers RH, Borecki IB, et al. Replication of linkage of familial combined hyperlipidemia to chromosome 1q with additional heterogeneous effect of apolipoprotein A-I/C-III/A-IV locus. The NHLBI Family Heart Study. Arterioscler Thromb Vasc Biol 2000; 20:2275-2280.
78. Pihlajamaki J, Karjalainen L, Karhapaa P, et al. G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2000; 20:1789-1795.
79. Hoffer MJ, Bredie SJ, Snieder H, et al. Gender-related association between the -93T->G/D9N haplotype of the lipoprotein lipase gene and elevated lipid levels in familial combined hyperlipidemia. Atherosclerosis 1998; 138:91-99.
80. Hoffer MJ, Snieder H, Bredie SJ, et al. The V73M mutation in the hepatic lipase gene is associated with elevated cholesterol levels in four Dutch pedigrees with familial combined hyperlipidemia. Atherosclerosis 2000; 151:443-450.
81. Pajukanta P, Porkka KV, Antikainen M, et al. No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in Finnish families. ArteriosclerThromb Vasc Biol 1 997; 17:841-850.
82. Civeira F, Jarauta E, Cenarro A, et al. Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting. J Am Coll Cardiol 2008; 52:1546-1553.
83. Abifadel M, Bernier L, DubucG, et al.A PCSK9 variant and familial combined hyperlipidaemia. J Med Genet 2008; 45:780-786.
84. Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375:1634-1639.
85. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375:1875-1884.
86. Ginsberg HN, Elam MB, LovatoLC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-1574.
87. Fabbrini E, Mohammed BS, Korenblat KM, et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010; 95:2727-2735.
88. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361:2113-2122.
89. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008; 101:625-630.
90. Joy TR, Hegele RA. Microsomal triglyceride transfer protein inhibition: friend or foe? Nat Clin Pract Cardiovasc Med 2008; 5:506-508.
91. Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008; 5:497-505.
92. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362:906-916.
93. Ladenson PW, McCarren M, Morkin E, et al. Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study. J Clin Endocrinol Metab 2010; 95:1349-1354.
94. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
95. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589.
96. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289.
97. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096-1105.
98. Pentikainen PJ, Voutilainen E, Aro A, et al. Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial. Ann Med 1990; 22:307-312.
99. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25:708-711.
100. Yki-Jarvinen H. Thiazolidinediones and the liver in humans. Curr Opin Lipidol 2009; 20:477-483.
101. Ravikumar B, Gerrard J, Dalla Man C, et al. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. Diabetes 2008; 57:2288-2295.
102. Nagashima K, Lopez C, Donovan D, et al. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005; 115:1323-1332.
103. Abbink EJ, De Graaf J, De Haan JH, et al. Effects of pioglitazone in familial combined hyperlipidaemia. J Intern Med 2006; 259:107-116.
104. Thomas EL, Potter E, Tosi I, et al. Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: relation to liver, muscle and regional body fat content. Atherosclerosis 2007; 195:e181-e190.
105. Defronzo RA, Banerji M, Bray GA, et al. Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord 2009; 9:17.